We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Capsida

News List

Capsida Unveils Next-Generation Gene Therapy Manufacturing contractpharma
July 28, 2021
New 15,000 square foot facility in Thousand Oaks will enable end-to-end gene therapy manufacturing capability.
Capsida Biotherapeutics Opens Facility in Thousand Oaks contractpharma
July 26, 2021
New 15,000 square-foot facility will enable industry leading end-to-end gene therapy manufacturing capability.
CRISPR, Capsida team up on gene-edited therapies for ALS, Friedreich's ataxia firstwordpharma
June 16, 2021
CRISPR Therapeutics has inked a partnership with newly launched Capsida Biotherapeutics to develop and commercialise in vivo gene-editing therapies delivered with engineered adeno-associated virus (AAV) vectors for the treatment of familial amyotrophic
Capsida Biotherapeutics Appoints CMO contractpharma
May 13, 2021
Capsida Biotherapeutics Inc., a biotechnology company developing targeted gene therapies using its next-generation adeno-associated virus (AAV) engineering platform, has appointed Swati Tole, M.D., as chief medical officer. Dr. Tole brings extensive ...